SCHEDULE 13G/A: T. Rowe Price Associates Updates Stake in Pliant Therapeutics, Reports 0.1% Beneficial Ownership
Beneficial Ownership Report
T. Rowe Price Associates, Inc. has filed an Amendment No. 2 to Schedule 13G, disclosing its beneficial ownership of 0.1% of Pliant Therapeutics Inc.'s common stock as of March 31, 2025.
Summary
- T. Rowe Price Associates, Inc., an investment adviser based in Baltimore, MD, filed an Amendment No. 2 to Schedule 13G regarding its holdings in Pliant Therapeutics Inc.
- As of March 31, 2025, T. Rowe Price Associates beneficially owns an aggregate of 87,674 shares of Pliant Therapeutics Inc. common stock.
- This ownership represents 0.1% of the total class of securities.
- The firm holds sole voting power over 81,601 shares and sole dispositive power over all 87,674 shares.
- No shared voting or dispositive power was reported.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine beneficial ownership filing (Schedule 13G Amendment No. 2) by an institutional investor, T. Rowe Price Associates, Inc. It reports a very small, passive stake (0.1%) in Pliant Therapeutics Inc. Such filings are generally neutral in sentiment as they reflect portfolio management rather than a significant change in the issuer's fundamentals or a strategic move by the investor to influence the company. The low percentage suggests it's not a highly impactful holding for the investor or the company.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by an institutional investor, T. Rowe Price Associates, Inc., regarding its passive investment in Pliant Therapeutics Inc., a biotechnology company. It does not provide specific insights into Pliant Therapeutics' operational performance or strategic direction, but rather reflects an investment firm's portfolio adjustments. Such filings are common for large asset managers who hold stakes in numerous public companies.
Stakeholder Impact
- Shareholders: Provides transparency regarding the beneficial ownership of a significant institutional investor, T. Rowe Price Associates, Inc., though the reported stake of 0.1% is very small and unlikely to influence company control or strategy.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement, indicating the beneficial ownership position. |
| 05/14/2025 | Date the Schedule 13G Amendment No. 2 was signed by T. Rowe Price Associates, Inc. |
Keywords
Pliant Therapeutics Inc., T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.